Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1N1 Pandemic Influenza Vaccine in Healthy Adults
NCT00959465Phase 2Completed
- Sponsor
- Resilience Government Services
- Start
- Aug 2009
- Primary completion
- Nov 2009
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of influenza A (H1N1) 2009 monovalent vaccine in Influenza A H1N1 (H1N1) (3 cohorts), sponsored by Resilience Government Services. Primary endpoint: Number of subjects achieving antibody levels to A/H1N1/California/07/2009 virus that meet the definition of seroprotection and seroconversion at 42 days. Started Aug 2009; status: completed.
02
Drugs
influenza A (H1N1) 2009 monovalent vaccine
03
Conditions
Influenza A H1N1 (H1N1)
Beyond the preview
Go deeper on NCT00959465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00959465.